SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI.X is trending as the community rallies around its potential as the next big meme coin on the Solana blockchain, drawing comparisons to $SHIB.X and $DOGE.X. Many community members express strong conviction and highlight the supportive community, while others emphasize its association with the $PUMP.X ecosystem.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies behind this Solana-based crypto, highlighting its locked liquidity and burned tokens. Discussions mention the coin's potential, joke-meta pioneer status, and growing community, with some comparing it to other meme coins like $SHIB.X and emphasizing its presence on Jupiter Exchange's strict list.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, fueled by significant institutional investments, with Galaxy Digital's recent acquisitions drawing considerable attention. The community is buzzing about potential price targets and the emergence of new projects and memecoins built on the Solana blockchain, such as $WAGMI.X and $UPDOG.X. Discussions also involve signals, predictions, and overall bullish sentiment surrounding Solana's potential within the broader crypto market.

Pump.fun

$PUMP.X is trending as users discuss its potential as a memecoin launchpad on Solana, highlighting its revenue model and community growth. Community members are actively discussing entry points, price targets, and whether it can reach the levels of coins like $DOGE.X. Some are pointing to potential catalysts, like exchange listings and upcoming events, that could drive further momentum.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending as traders assess the potential impact of recent economic data, including a weaker-than-expected jobs report, on future Federal Reserve policy. Community discussions revolve around the likelihood of rate cuts and their potential effects, while some express concerns about market manipulation and the reliability of economic data. A court decision impacting tariffs is also adding to the uncertainty.

Flare is a blockchain for building applications that are interoperable with other blockchains and the internet.  ## What is Flare (FLR)?  Flare is an EVM-based Layer 1 blockchain designed to allow developers to build applications that are interoperable with blockchains and the internet. By providing decentralized access to high-integrity data, Flare enables new use cases and monetisation models.   ## What makes Flare unique?  Flare's native interoperability protocols, the State Connector and the FTSO are secured by the network itself, allowing it to reliably deliver data from a wide variety of off-chain sources in a decentralized way.   The Flare Time Series Oracle delivers highly-decentralized price and data feeds to dapps on Flare, without relying on centralized providers.   The State Connector protocols enable information, both from other blockchains and the internet to be used securely, scalably and trustlessly with smart contracts on Flare.  Risk is minimized by building this decentralized data infrastructure natively into the blockchain, powered by a large number of independent data providers.  By incentivizing sets of independent providers to query, acquire, and process data without relying on single, centralized sources, Flare’s core protocols can facilitate the development of interoperable dapps with a broad range of potential innovative use cases.   ## What is the Flare (FLR) token used for?  FLR is the native token used for payments, transaction fees to prevent spam attacks and staking in validator nodes. FLR can also be wrapped into an ERC-20 variant, WFLR. WFLR tokens serve various functions; they can be delegated to FTSO data providers, for example, or staked to participate in governance. These two uses are not mutually exclusive and do not prevent the tokens from being used in other EVM-compatible dapps and smart contracts on Flare.  Wrapped FLR (WFLR) can be minted by depositing native FLR tokens into a smart contract and withdrawing the newly minted

Spark Token

Spark Token ($FLR.X) is trending as community members discuss its potential within the XRP ecosystem and its possible integration with staking platforms. The recent buzz is fueled by news of adoption headlines and staking rewards via monthly airdrops. Some investors are optimistic about its long-term growth, drawing comparisons to other successful tokens and anticipating a significant rise in value.

Dolomite

Dolomite (DOLO.X) is trending as community members discuss potential catalysts and compare it to other recently volatile altcoins. The community is speculating about factors driving the price and expressing excitement about potential gains. Mentions of related tokens and possible listings are circulating among traders.

HarryPotterObamaSonic10Inu (Ticker: BITCOIN) is a endgame of crypto-assets (0 Tax). BITCOIN incentivizes the creation of novel and entertaining meme content. With ownership renounced and Liquidity locked, our robust growing community has taken the lead; we have successfully completed a full audit, an NFT collection, and are exploring partnerships with other tokens in the space, a one-of-a -kind website, and one-of-a-kind merchandise and ecommerce site in the works based on the legendary meme that inspired BITCOIN's creation. Our goal is to create an ecosystem for active community members to meet, collaborate, and share our rich lore (the archive of our token's storied history) with the world.

hposI0iETH

Bitcoin's recent activity has spurred discussions around its potential to outperform traditional stocks, with community members analyzing chart patterns and debating future price movements. Some users are comparing it to other cryptocurrencies and memecoins, while others are discussing broader narratives around tokenization and the potential impact of regulatory approvals. The community also seems to be focused on the relationship between Bitcoin and specific altcoins.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad ($GIGA.X) is trending as community members discuss its potential within the meme coin sector, drawing comparisons to other popular coins and highlighting its strong community. Recent social media activity, including a YouTuber meeting the real Gigachad, may be contributing to the increased attention. Some traders are also watching its correlation to Solana ($SOL.X) for potential movement.

In a crypto world of meme coins kekistan is it's home.  Is goes back to mid 2000s being a 4chan community. The birth place of Pepe the frog, This community  has brought other communities together  to support something  in crypto and real life. We have rebranded a token. Bringing fun and happy environment. Were actually  the 3rd place in our communities life.  The first place being  home and family  time. The 2nd  is workplace. And were the 3rd place at the end of the day we are there they relax and enjoy themselves

Kekistan

Kekistan ($KEK.X) is trending as community members rally around the meme-based cryptocurrency, celebrating its origins from 4chan and its potential for significant growth. The community emphasizes the power of memes and the vision of a decentralized, meme-driven future. Many reference the coin's history and connection to internet culture.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IOVA Stock Drops 6% on $350M Common Stock Offering

Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline. 

Shares of Iovance Biotherapeutics Inc. (IOVA) traded 4% higher on Tuesday morning after Health Canada approved the company’s immunotherapy for the treatment of advanced melanoma.On Stocktwits, retail sentiment around IOVA rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter around <a href="https://stocktwits.com/symbol/IOVA">IOVA</a> jumped 782% over the past 24 hours as of Tuesday's early hours and by 87% over the past seven days.<figure class="image"><img style="aspect-ratio:626/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_11_53_05_AM_png_6c5efda32c.webp" alt="IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="626" height="61"><figcaption>IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock would have risen further had it not been for an overall market downturn and said that ‘patience will pay off.’<stembedurl>https://stocktwits.com/katanare/message/625784957</stembedurl>Iovance’s Amtagvi is a T-cell immunotherapy for the treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy and who have no satisfactory alternative treatment options. Advanced melanoma, also known as metastatic melanoma, refers to melanoma that has spread from the original site to other parts of the body.The marketing authorization in Canada was <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvir-lifileucel-receives-health-canada-approval">granted</a> based on the safety and efficacy results from a mid-stage trial. The approval is conditional, pending results of trials to confirm its clinical benefit. However, for Iovance, the approval marks its first outside the U.S. “We expect to authorize our first Canadian treatment center within the next few months, and we continue to advance our ex-U.S. strategy for Amtagvi in additional markets,” said CEO Frederick Vogt.Iovance is also investigating Amtagvi in frontline advanced melanoma in a late-stage trial, as well as in additional solid tumor types. IOVA stock is down by 65% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/william-blair-highlights-tesla-robotaxi-upsides-versus-uber-waymo/chsgZU4RdgC">William Blair Highlights Tesla Robotaxi’s Upsides Versus Uber, Waymo: Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’

The approval from Health Canada is conditional, pending results of trials to confirm the immunotherapy’s clinical benefit.

Equity

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Iovance Biotherapeutics have dropped over 17% so far this week, on course to mark their worst weekly decline since mid-November 2024.&nbsp;The selloff aligns with broader pressure on small-cap stocks within the Russell 2000 index, which is sliding into correction territory as fears over prolonged higher interest rates grip the market.Macroeconomic concerns have intensified following robust U.S. jobs data, showing accelerating job growth and a lower unemployment rate of 4.1% in December.&nbsp;Small and mid-cap companies, like Iovance, are particularly sensitive to rate dynamics due to their reliance on borrowing compared to larger companies.<figure class="image"><img style="aspect-ratio:1314/1036;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IOVA_poll_sentiment_and_message_volume_Jan_10_95fa61f76a.png" alt="IOVA poll sentiment and message volume Jan 10.png" width="1314" height="1036"><figcaption>IOVA poll sentiment and message volume Jan 10 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the macro-driven plunge, sentiment for Iovance has turned ‘extremely bullish’ on Stocktwits, with the stock becoming one of the platform’s top three trending tickers on Friday afternoon.&nbsp;Many retail investors see the selloff as overdone, drawing attention to the company’s promising medical pipeline and proprietary technology.<stembedurl>https://stocktwits.com/thebullofwallst/message/599572619</stembedurl><stembedurl>https://stocktwits.com/parsnips/message/599576937</stembedurl>Some also speculated on the possibility of acquisition interest, citing Vertex Pharmaceuticals’ $4.9 billion premium buyout of Alpine Immune Sciences in 2024 as a precedent.&nbsp;<stembedurl>https://stocktwits.com/AngusMacbeth/message/599584221</stembedurl>In November, Iovance CEO Frederick Vogt highlighted the strong U.S. launch of Amtagvi for advanced melanoma and its growing demand through an expanding network of authorized treatment centers. "As a fully integrated company, Iovance is well positioned to remain the global leader in innovating, developing, and delivering current and future generations of TIL cell therapy for patients with cancer," he added.Tumor-infiltrating lymphocyte (TIL) therapy is an innovative, patient-specific approach that uses T-lymphocytes derived from a patient’s tumor to combat cancer cells.Retail optimism about TIL therapy remains high, with 67% of respondents in a Stocktwits poll calling it a “game-changer” in cancer treatment.&nbsp;The therapy this week gained visibility as MedStar Georgetown University Hospital became the first in the Washington, D.C., area to offer it for metastatic melanoma.Iovance’s retail following has grown by 65% over the past year, even as the stock has shed more than 30% during the same period.The company’s stock remains a battleground for investors, with short interest hovering at 19.5%.&nbsp;While macroeconomic challenges weigh on small caps, retail investors remain steadfast in their optimism, betting on TIL therapy’s transformative potential to reshape cancer treatment.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown

In November, Iovance CEO Frederick Vogt highlighted the strong U.S. launch of Amtagvi for advanced melanoma and its growing demand through an expanding network of authorized treatment centers.

Iovance Stock Tumbles On Macro Concerns, But Retail Stays Bullish On TIL Cancer Therapy Potential

This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon PR Newswire VANCOUVER, BC, Nov. 14, 2024 USA News...

A Peek at Iovance Biotherapeutics's Future Earnings

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOVA News

IOVA Iovance Biotherapeutics Inc